Piper Jaffray Downgrades Impax Laboratories (IPXL) to Underweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Impax Laboratories (IPXL) PT Lowered to $10 at RBC Capital
March 2, 2017 6:19 AM ESTRBC Capital lowered its price target on Impax Laboratories (NASDAQ: IPXL) to $10.00 (from $15.00) while maintaining a Sector Perform rating following results
Analyst Randall Stanicky commented, "The stock was down -35% following IPXL's 4Q results and first-time 2017 update (no revenue or EPS... More
Impax Laboratories (IPXL) Reports In-Line Q4 EPS
March 1, 2017 6:36 AM ESTImpax Laboratories (NASDAQ: IPXL) reported Q4 EPS of $0.16, in-line with the analyst estimate of $0.16. Revenue for the quarter came in at $198.4 million versus the consensus estimate of $219.25 million.
For earnings history and earnings-related data on Impax Laboratories (IPXL) click here.
... More